The pretreatment of the NF-κB inhibitor obviously decreased the expression of PD-L1, which indicated that the NF-κB pathway participated in PD-L1 transcription in PDAC cancer cells (Figs. 5D and S5D). This evidence concerns the gene NFKB1 and cancer.